Age as prognostic factor in patients with osteosarcoma
- PMID: 21893224
- DOI: 10.1016/j.bone.2011.08.014
Age as prognostic factor in patients with osteosarcoma
Abstract
Age at diagnosis is a well known prognostic factor in many different malignancies; its significance for patients with osteosarcoma is however controversial. To gain more insight in the prognostic role of age, we performed a retrospective study at our institute. We included 102 patients with de-novo osteosarcoma and formed three age groups to evaluate age specific survival rates: ≤ 14 years, 15-19 years and 20-40 years. Differences in outcome between patients aged 15-19 years treated at either the pediatric department or the adult department of oncology were evaluated. The 5-year overall survival rate (OSR) of the whole population was 53.5%±1.5%. OSR of 70.6%±0.8% was seen in patients ≤ 14 years old, 52.5%±1.1% in patients 15-19 years old and 33.3%±0.9% in the patients aged 20-40 years (p=0.01). Significant differences were observed with regard to stage at presentation (higher in older age groups), size of the tumor (larger in younger age groups) and histological response (more good responders in younger age groups). No significant difference was seen between outcomes of patients aged 15-19 years treated at the pediatric or adult oncology department. In conclusion, younger patients have a significantly better outcome than older patients.
Copyright © 2011 Elsevier Inc. All rights reserved.
Similar articles
-
Primary metastatic osteosarcoma: presentation and outcome of patients treated on neoadjuvant Cooperative Osteosarcoma Study Group protocols.J Clin Oncol. 2003 May 15;21(10):2011-8. doi: 10.1200/JCO.2003.08.132. J Clin Oncol. 2003. PMID: 12743156
-
Prognostic factors for osteosarcoma of the extremity treated with neoadjuvant chemotherapy: 15-year experience in 789 patients treated at a single institution.Cancer. 2006 Mar 1;106(5):1154-61. doi: 10.1002/cncr.21724. Cancer. 2006. PMID: 16421923
-
Non-metastatic osteosarcoma of the extremities in children aged 5 years or younger.Pediatr Blood Cancer. 2010 Oct;55(4):652-4. doi: 10.1002/pbc.22567. Pediatr Blood Cancer. 2010. PMID: 20806363
-
The epidemiology of osteosarcoma.Cancer Treat Res. 2009;152:3-13. doi: 10.1007/978-1-4419-0284-9_1. Cancer Treat Res. 2009. PMID: 20213383 Review.
-
Osteosarcoma in Pediatric and Adult Populations: Are Adults Just Big Kids?Cancers (Basel). 2023 Oct 19;15(20):5044. doi: 10.3390/cancers15205044. Cancers (Basel). 2023. PMID: 37894411 Free PMC article. Review.
Cited by
-
Osteosarcoma in patients below 25 years of age: An observational study of incidence, metastasis, treatment and outcomes.Oncol Lett. 2018 Nov;16(5):6502-6514. doi: 10.3892/ol.2018.9453. Epub 2018 Sep 18. Oncol Lett. 2018. PMID: 30405789 Free PMC article.
-
Clinicopathological correlations and prognostic insights in osteosarcoma: a retrospective analysis.Rom J Morphol Embryol. 2024 Oct-Dec;65(4):723-736. doi: 10.47162/RJME.65.4.19. Rom J Morphol Embryol. 2024. PMID: 39957034 Free PMC article.
-
Development and validation of an online prognostic nomogram for osteosarcoma after surgery: a retrospective study based on the SEER database and external validation with single-center data.Transl Cancer Res. 2022 Sep;11(9):3156-3174. doi: 10.21037/tcr-21-2756. Transl Cancer Res. 2022. PMID: 36237232 Free PMC article.
-
Disease progression in osteosarcoma: a multistate model for the EURAMOS-1 (European and American Osteosarcoma Study) randomised clinical trial.BMJ Open. 2022 Mar 4;12(3):e053083. doi: 10.1136/bmjopen-2021-053083. BMJ Open. 2022. PMID: 35246418 Free PMC article. Clinical Trial.
-
Investigating age‑induced differentially expressed genes and potential molecular mechanisms in osteosarcoma based on integrated bioinformatics analysis.Mol Med Rep. 2019 Apr;19(4):2729-2739. doi: 10.3892/mmr.2019.9912. Epub 2019 Jan 30. Mol Med Rep. 2019. PMID: 30720085 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical